Lurbinectedin is a medication used in the treatment of certain types of cancer. It is important to consider any potential adverse effects that may arise when combining lurbinectedin with other medications or treatments. While the provided sources do not specifically address the adverse effects of combining lurbinectedin with other substances, they do provide valuable information about the drug itself and its use in clinical trials.

According to the drug patent watch website, lurbinectedin is a novel antineoplastic agent that has shown promise in treating various types of cancer. It is a selective inhibitor of RNA polymerase II, which plays a crucial role in gene transcription. However, the website does not mention any specific adverse effects associated with combining lurbinectedin with other drugs [1].

The PubMed article mentioned provides insights into the efficacy and safety of lurbinectedin in treating advanced solid tumors. It discusses the results of a phase I clinical trial, which evaluated the drug's tolerability and potential side effects. While the study does mention some adverse effects, such as nausea, fatigue, and hematological toxicity, it does not specifically address the adverse effects of combining lurbinectedin with other substances [2].

The clinical trial search on the National Cancer Institute website provides information about ongoing clinical trials involving lurbinectedin. These trials aim to evaluate the drug's effectiveness and safety in combination with other treatments. However, the provided source does not directly discuss the adverse effects of combining lurbinectedin with other substances [3].

Given the limited information available in the provided sources, it is difficult to provide a comprehensive answer regarding the adverse effects of combining lurbinectedin with other substances. It is crucial to consult with healthcare professionals, such as oncologists or pharmacists, who can provide more specific information about potential drug interactions and adverse effects based on individual patient characteristics and medical history.

In conclusion, while the provided sources offer valuable information about lurbinectedin and its use in clinical trials, they do not specifically address the adverse effects of combining lurbinectedin with other substances. It is essential to consult healthcare professionals for more specific information regarding potential drug interactions and adverse effects.

Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] PubMed. Phase I study of lurbinectedin (PM01183) in advanced solid tumors. Retrieved from https://pubmed.ncbi.nlm.nih.gov/36252599/
[3] National Cancer Institute. Clinical Trials Search: Lurbinectedin. Retrieved from https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-00578